Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin in Aggressive Systemic Mastocytosis or Mast Cell Leukemia
2008-000280-42Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midostaurin in Aggressive Systemic Mastocytosis (ASM), mast cell leukemia (MCL) and hematopoietic malignancies, sponsored by Novartis. Primary endpoint: Overall response rate (ORR). Started Jul 2008; status: completed.
02
Drugs
midostaurin
03
Conditions
Aggressive Systemic Mastocytosis (ASM)mast cell leukemia (MCL)hematopoietic malignancies
Beyond the preview
Go deeper on 2008-000280-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000280-42.